Table 3.
Association between residual symptoms domains, pain and functioning
| Odds Ratio | 95% Wald Confidence Limits | ||
|---|---|---|---|
|
Age |
0.990 |
0.975 |
1.005 |
|
Gender (male vs. female) |
1.356 |
0.886 |
2.076 |
|
Academic degree (high vs. other) |
1.580 |
0.949 |
2.629 |
|
Baseline functioning level (SOFAS) |
1.049 |
1.031 |
1.067 |
|
Episode length (4–24 weeks vs. ≥ 24 weeks) |
2.008 |
1.127 |
3.579 |
|
Episode lenght (≤4 weeks vs. ≥24 weeks) |
2.138 |
1.145 |
3.992 |
|
Absence of residual core mood symptoms |
8.728 |
4.553 |
16.730 |
|
Absence of residual insomnia symptoms |
1.796 |
1.175 |
2.744 |
|
Absence of residual anxiety symptoms and absence of pain |
5.257 |
2.445 |
11.300 |
|
Absence of residual anxiety symptoms and presence of pain |
0.412 |
0.073 |
2.341 |
|
Absence of pain and absence of residual anxiety symptoms |
21.669 |
3.544 |
132.498 |
| Absence of pain and presence of residual anxiety symptoms | 1.700 | 1.025 | 2.819 |
Logistic regression model.
SOFAS = Social and Occupational Functioning Assessment Scale;
Dependent variable: normal level of functioning (SOFAS total score ≥80) after 3 months of antidepressant treatment.